{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:57:11Z","timestamp":1767193031717,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.revmed.2023.10.438","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T01:51:05Z","timestamp":1703814665000},"page":"41-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnostic et \u00e9valuation de l\u2019h\u00e9patopathie st\u00e9atosique m\u00e9tabolique"],"prefix":"10.1016","volume":"45","author":[{"given":"C.M.","family":"Canivet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Faure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.revmed.2023.10.438_bib0320","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of non-alcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.revmed.2023.10.438_bib0325","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: hepatology","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.revmed.2023.10.438_bib0330","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of non-alcoholic steatohepatitis. Longo DL, editor","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2023.10.438_bib0335","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/ajg.2014.134","article-title":"Non-alcoholic fatty liver disease is underrecognized in the primary care setting","volume":"110","author":"Blais","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.revmed.2023.10.438_bib0340","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.revmed.2023.10.438_bib0345","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.revmed.2023.10.438_bib0350","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for non-alcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.revmed.2023.10.438_bib0355","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.revmed.2023.10.438_bib0360","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.revmed.2023.10.438_bib0365","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.revmed.2023.10.438_bib0370","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with non-alcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2023.10.438_bib0375","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/TP.0000000000002484","article-title":"Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: implications for liver transplantation","volume":"103","author":"Younossi","year":"2019","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.revmed.2023.10.438_bib0380","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.gastro.2020.04.048","article-title":"Prevalence and risk factors of non-alcoholic fatty liver disease and advanced fibrosis in general population: the French Nationwide NASH-CO Study","volume":"159","author":"Nabi","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.revmed.2023.10.438_bib0385","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","article-title":"NAFLD and liver transplantation: current burden and expected challenges","volume":"65","author":"Pais","year":"2016","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.revmed.2023.10.438_bib0390","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s10620-017-4684-x","article-title":"Liver transplantation for non-alcoholic steatohepatitis in the US: tdemporal trends and outcomes","volume":"62","author":"Cholankeril","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.revmed.2023.10.438_bib0395","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.revmed.2023.10.438_bib0400","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed non-alcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2020","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.revmed.2023.10.438_bib0405","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced non-alcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.revmed.2023.10.438_bib0410","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of non-alcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.revmed.2023.10.438_bib0415","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward genetic prediction of non-alcoholic fatty liver disease trajectories: PNPLA3\u00a0and beyond","volume":"158","author":"Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.revmed.2023.10.438_bib0420","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology","volume":"17","author":"Eslam","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.revmed.2023.10.438_bib0425","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: a major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.revmed.2023.10.438_bib0430","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.revmed.2023.10.438_bib0435","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.revmed.2023.10.438_bib0440","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.jhep.2008.01.014","article-title":"Iron and the liver: update 2008","volume":"48","author":"Deugnier","year":"2008","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.revmed.2023.10.438_bib0445","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2337\/dc12-0505","article-title":"Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study","volume":"36","author":"Wlazlo","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.revmed.2023.10.438_bib0450","unstructured":"Boursier J. Recommandation AFEF pour le diagnostic et le suivi non invasif des maladie chroniques du foie. https:\/\/afef.asso.fr\/wp-content\/uploads\/2020\/07\/DNI-VERSION-FINALE-RECO-2020.pdf."},{"issue":"16","key":"10.1016\/j.revmed.2023.10.438_bib0455","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.revmed.2023.10.438_bib0460","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2004.10.005","article-title":"Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma","volume":"42","author":"Marrero","year":"2005","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.revmed.2023.10.438_bib0465","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for non-alcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2023.10.438_bib0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u00a0\u2013\u00a02021\u00a0update","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.revmed.2023.10.438_bib0475","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.revmed.2023.10.438_bib0480","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.revmed.2023.10.438_bib0485","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.revmed.2023.10.438_bib0490","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/hep4.1208","article-title":"A pragmatic approach identifies a high rate of non-alcoholic fatty liver disease with advanced fibrosis in diabetes clinics and at-risk populations in primary care","volume":"2","author":"Patel","year":"2018","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.revmed.2023.10.438_bib0495","doi-asserted-by":"crossref","first-page":"e000904","DOI":"10.1136\/bmjdrc-2019-000904","article-title":"Screening for non-alcoholic fatty liver disease in type 2\u00a0diabetes using non-invasive scores and association with diabetic complications","volume":"8","author":"Ciardullo","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.revmed.2023.10.438_bib0500","article-title":"Impact of type 2\u00a0diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications","author":"Boursier","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.revmed.2023.10.438_bib0505","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.revmed.2023.10.438_bib0510","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.revmed.2023.10.438_bib0515","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"issue":"13","key":"10.1016\/j.revmed.2023.10.438_bib0520","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.3390\/jcm10132910","article-title":"Systematic review with meta-analyses: diagnostic accuracy of fibrometer tests in patients with non-alcoholic fatty liver disease","volume":"10","author":"Van Dijk","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.revmed.2023.10.438_bib0525","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Non-invasive assessment of liver disease in patients with non-alcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.revmed.2023.10.438_bib0530","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.revmed.2023.10.438_bib0535","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.revmed.2023.10.438_bib0540","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.revmed.2023.10.438_bib0545","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.revmed.2023.10.438_bib0550","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of non-alcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.revmed.2023.10.438_bib0555","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.clnu.2020.09.001","article-title":"ESPEN practical guideline: clinical nutrition in liver disease","volume":"39","author":"Bischoff","year":"2020","journal-title":"Clin Nutr"},{"issue":"12","key":"10.1016\/j.revmed.2023.10.438_bib0560","doi-asserted-by":"crossref","first-page":"E2991","DOI":"10.3390\/nu11122991","article-title":"Experimental outcomes of the Mediterranean diet: lessons learned from the predimed randomized controlled trial","volume":"11","author":"Kargin","year":"2019","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.revmed.2023.10.438_bib0565","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Non-alcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.revmed.2023.10.438_bib0570","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of non-alcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.revmed.2023.10.438_bib0575","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.32439","article-title":"Diabetes medications and risk of HCC","volume":"76","author":"Plaz Torres","year":"2022","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.revmed.2023.10.438_bib0580","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.revmed.2023.10.438_bib0585","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in non-alcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2023.10.438_bib0590","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1\u00a0receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.revmed.2023.10.438_bib0595","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in patients with biopsy-confirmed non-alcoholic fatty liver disease: a population-based cohort study","volume":"74","author":"Simon","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.revmed.2023.10.438_bib0600","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: expert review","volume":"156","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.revmed.2023.10.438_bib0605","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.04.027","article-title":"Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study","volume":"155","author":"Costentin","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.revmed.2023.10.438_bib0610","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jhep.2016.10.015","article-title":"Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country","volume":"66","author":"Goutt\u00e9","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.revmed.2023.10.438_bib0615","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.revmed.2023.10.438_bib0620","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2023.10.438_bib0625","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-142-1-200501040-00110","article-title":"Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality","volume":"142","author":"Miller","year":"2005","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.revmed.2023.10.438_bib0315","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for non-alcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323008809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323008809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:47:08Z","timestamp":1759337228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866323008809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0248866323008809"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2023.10.438","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic et \u00e9valuation de l\u2019h\u00e9patopathie st\u00e9atosique m\u00e9tabolique","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2023.10.438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}